SCHEMBL12820105

SCHEMBL12820105

COC(=O)C[C@H](C)Cc1ccccc1N

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.41
CFTR P13569 1/20 0.41
HSD17B10 Q99714 1/20 0.41
KDM4E B2RXH2 3/20 0.40
MEN1 O00255 1/20 0.40
USP2 O75604 1/20 0.40
APOBEC3A P31941 1/20 0.40
KMT2A Q03164 1/20 0.40
KEAP1 Q14145 1/20 0.40
NFE2L2 Q16236 1/20 0.40
APOBEC3G Q9HC16 1/20 0.40
HPGD P15428 3/20 0.40
RCE1 Q9Y256 1/20 0.40
KCNA5 P22460 1/20 0.39
HTT P42858 1/20 0.38
MAPT P10636 1/20 0.38
RAB9A P51151 1/20 0.38
ESR1 P03372 1/20 0.38
KCNH2 Q12809 1/20 0.38
TSHR P16473 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22751884 0.83 KDM4E (0.47) ALDH1A1KDM4EHPGDKCNA5HTT
SCHEMBL7710944 0.83 AKR1B1 (0.42) HPGDKCNA5HTTMAPTRAB9A
SCHEMBL10509525 0.77 NPC1 (0.51) ALDH1A1HSD17B10MEN1KMT2AKCNA5
SCHEMBL4657688 0.77 POLB (0.49) ALDH1A1MEN1KMT2AHPGDRAB9A
SCHEMBL644296 0.76 ALDH1A1 (0.49) ALDH1A1CFTRHSD17B10KDM4EMEN1
SCHEMBL4027526 0.75 MEN1 (0.44) ALDH1A1KDM4EMEN1KMT2AHPGD
Hydrochloric Acid SCHEMBL1772178 0.75 ALDH1A1 (0.47) ALDH1A1CFTRHSD17B10KDM4EMEN1
Hydrochloric Acid SCHEMBL31720563 0.75 ALDH1A1 (0.47) ALDH1A1CFTRHSD17B10KDM4EMEN1
SCHEMBL28216115 0.74 ATM (0.46) ALDH1A1HSD17B10HPGDHTTMAPT
SCHEMBL20749099 0.74 TRPA1 (0.41) ESR1KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2011035417-A1 HSP-90 BINDING COMPOUNDS, COMPOSITIONS THEREOF, AND THEIR USE FN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISEASES AEGERA THERAPEUTICS INC. (CA) 2011-03-31 WO disclosed